After percutaneous coronary intervention (PCI) stenting, how long should we wait before restarting apixaban (Eliquis)?

Timing of Apixaban Restart After PCI Stenting

Apixaban can be restarted within 24 hours after PCI in most patients, and may be resumed as early as the evening of the procedure day depending on hemostasis and bleeding risk. 1

Evidence-Based Timing Algorithm

The 2020 ACC Expert Consensus provides clear guidance on anticoagulation reinitiation post-PCI 1:

Standard Approach (Most Patients)

• Resume within 24 hours after PCI
• As early as same evening of PCI in select cases
• Decision made collaboratively with interventional cardiologist

Risk-Stratified Timing for Special Cases

For patients unable to take oral medications post-PCI (e.g., intubated):

• Low bleeding risk: Consider parenteral anticoagulation within 24 hours
• High bleeding risk: Consider parenteral anticoagulation within 48-72 hours 1

Alternatively, crushed apixaban tablets can be administered via nasogastric tube if needed 2

Critical Pre-Restart Assessment

Before reinitiating apixaban, evaluate 1:

1. Access site hemostasis (primary concern)
2. Recent bleeding history
3. Body habitus (obese patients with femoral access at higher risk)
4. Platelet function (qualitative/quantitative abnormalities)
5. Coagulation studies
6. Post-PCI renal function (may require dose adjustment) 1

Post-PCI Dosing Considerations

Use standard FDA-approved apixaban doses for atrial fibrillation or VTE as part of combination therapy 1:

• Standard dose: 5 mg twice daily
• Reduced dose: 2.5 mg twice daily (if ≥2 criteria: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 2

Important distinction: Unlike rivaroxaban (which requires dose reduction during antiplatelet therapy), apixaban uses standard FDA-approved doses throughout the post-PCI period 1

Antiplatelet Combination Strategy

The evidence strongly supports dual therapy (apixaban + P2Y12 inhibitor) without aspirin as the default post-PCI strategy 3, 4:

• Clopidogrel preferred as the P2Y12 inhibitor 1, 5
• Aspirin should be stopped at discharge in most patients 5
• Triple therapy (if used) limited to ≤1 month maximum in high thrombotic/low bleeding risk patients 1, 5

This approach is supported by the AUGUSTUS trial, which demonstrated that apixaban without aspirin resulted in 69% reduction in major/clinically relevant bleeding compared to warfarin (HR 0.69,95% CI 0.58-0.81, P<0.001), and 89% increase in bleeding with aspirin versus placebo (HR 1.89,95% CI 1.59-2.24, P<0.001) 3

Common Pitfalls to Avoid

1. Don't delay unnecessarily: The 24-hour window is a maximum, not a target—earlier restart is appropriate if hemostasis is adequate
2. Don't bridge with parenteral anticoagulation in most patients—this is only for select high thromboembolic risk cases 1
3. Don't reduce apixaban dose during antiplatelet therapy unless standard dose-reduction criteria are met 1
4. Don't continue triple therapy beyond 30 days except in exceptional circumstances 1, 5

Real-World Data Context

In the ARISTOTLE PCI substudy, among patients who underwent PCI while on study drug 6:

• 19% continued anticoagulation without interruption during PCI
• 49% restarted within 5 days post-PCI
• Only 30% restarted >5 days post-PCI

This real-world pattern supports early reinitiation, though practice varied considerably before current guidelines.